- NASDAQ:MRNA falls 3.58% despite a market rally coming out of the MLK holiday.
- The state of California halts the issuance of Moderna’s vaccine candidate because of allergic reactions.
- Moderna’s CEO likens the COVID-19 vaccine market to the seasonal flu.
NASDAQ:MRNA has carried its momentum from the end of 2020 into 2021 so far as the stock has steadily risen throughout the first two trading weeks of the new year. On Tuesday, following the MLK extended holiday in the United States, Moderna shed 3.58% amidst a global market rally that saw the NASDAQ add 1.53% and the S&P 500 add 30 basis points. Moderna continues to be a global leader in the ongoing fight against the novel coronavirus, and investors have reaped the rewards as the stock is up nearly 520% over the past 52-weeks.
The pullback in price may be related to a recent report out of California that health officials had ordered a halt to the issuance of Moderna’s vaccine candidate mRNA-1273 due to allergic reactions from patients. This is not the first time that the issue of allergies has arisen, as Moderna’s rival Pfizer (NYSE:PFE) also reported reactions when its vaccine was issued in the United Kingdom. Apparently, over 300,000 vaccine doses have been put on pause until health officials can find out more about the reactions, which came from one specific clinic. The shipment that was delivered to that clinic, however, was a part of a larger shipment that distributed over 1.2 million doses around the United States.
MRNA stock price news
Recently, Moderna CEO Stephane Bancel caught the ear of investors when he stated that the COVID-19 vaccine could be a recurring seasonal dosage. While this isn’t great news for the population as a whole, it seems Moderna is expecting a recurring revenue stream from mRNA-1273 moving forward. Moderna is already expecting an estimated $11 billion in 2021 from mRNA-1273 alone.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.